Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionomics Limited stock logo
BNOX
Bionomics
$0.25
$0.27
$0.18
▼
$0.94
$4.47M0.266.12 million shsN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.95
+2.8%		$1.57
$0.59
▼
$1,030.00
$18.29M-2.2693,983 shs32,178 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.48
+0.5%		$0.50
$0.28
▼
$2.06
$16.06M0.29317,107 shs43,254 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$0.45
+2.3%		$0.65
$0.39
▼
$1.98
$17.11M1.62372,458 shs55,308 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionomics Limited stock logo
BNOX
Bionomics
0.00%0.00%0.00%0.00%0.00%
KALA BIO, Inc. stock logo
KALA
KALA BIO
0.00%+27.04%+12.15%-67.58%-99.76%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00%-5.17%+5.10%-38.41%-33.08%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
0.00%-9.36%-35.48%-45.19%-63.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bionomics Limited stock logo
BNOX
Bionomics
$0.25
$0.27
$0.18
▼
$0.94
$4.47M0.266.12 million shsN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
$0.95
+2.8%		$1.57
$0.59
▼
$1,030.00
$18.29M-2.2693,983 shs32,178 shs
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
$0.48
+0.5%		$0.50
$0.28
▼
$2.06
$16.06M0.29317,107 shs43,254 shs
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
$0.45
+2.3%		$0.65
$0.39
▼
$1.98
$17.11M1.62372,458 shs55,308 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bionomics Limited stock logo
BNOX
Bionomics
0.00%0.00%0.00%0.00%0.00%
KALA BIO, Inc. stock logo
KALA
KALA BIO
0.00%+27.04%+12.15%-67.58%-99.76%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
0.00%-5.17%+5.10%-38.41%-33.08%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
0.00%-9.36%-35.48%-45.19%-63.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bionomics Limited stock logo
BNOX
Bionomics
0.00
N/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
2.00
Hold$1,158.33121,829.82% Upside
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.67
Moderate Buy$3.00524.35% Upside
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
2.60
Moderate Buy$8.501,775.97% Upside

Current Analyst Ratings Breakdown

Latest BNOX, KALA, NRSN, and KTTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/30/2026
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/24/2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/16/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
6/1/2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bionomics Limited stock logo
BNOX
Bionomics
$10K446.82N/AN/A$1.32 per share0.19
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/A$12.56 per shareN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/A$2.39 per shareN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/A($0.05) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bionomics Limited stock logo
BNOX
Bionomics
-$15.49MN/AN/AN/AN/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$26.98M-$96.14N/AN/AN/AN/A-1,336.10%-94.85%8/17/2026 (Estimated)
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$20.43M-$1.58N/AN/AN/AN/A-57.44%-53.61%N/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
-$11.12M-$0.54N/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)

Latest BNOX, KALA, NRSN, and KTTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/17/2026Q2 2026
KALA BIO, Inc. stock logo
KALA
KALA BIO
-$6.00N/AN/AN/AN/AN/A
8/14/2026Q2 2026
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
-$0.16-$0.16N/A-$0.16$0.30 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bionomics Limited stock logo
BNOX
Bionomics
N/AN/AN/AN/AN/A
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/AN/AN/AN/AN/A
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/AN/AN/AN/AN/A
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bionomics Limited stock logo
BNOX
Bionomics
N/A
3.30
3.30
KALA BIO, Inc. stock logo
KALA
KALA BIO
N/A
7.91
7.91
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
N/A
35.41
35.41
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
N/A
0.31
0.31

Institutional Ownership

CompanyInstitutional Ownership
Bionomics Limited stock logo
BNOX
Bionomics
15.90%
KALA BIO, Inc. stock logo
KALA
KALA BIO
24.61%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
23.92%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1.04%

Insider Ownership

CompanyInsider Ownership
Bionomics Limited stock logo
BNOX
Bionomics
0.69%
KALA BIO, Inc. stock logo
KALA
KALA BIO
2.24%
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
2.00%
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
27.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bionomics Limited stock logo
BNOX
Bionomics
N/A17.65 million17.53 millionNot Optionable
KALA BIO, Inc. stock logo
KALA
KALA BIO
3019.34 million18.91 millionNot Optionable
Pasithea Therapeutics Corp. stock logo
KTTA
Pasithea Therapeutics
333.41 million32.75 millionNot Optionable
NeuroSense Therapeutics Ltd. stock logo
NRSN
NeuroSense Therapeutics
1037.77 million27.42 millionNot Optionable

Recent News About These Companies

Neurosense Therapeutics (NRSN) Stock Forecast & Price Target
August 13 at 10:47 PM  |  investing.comhttps://www.investing.com/equities/neurosense-therapeutics-consensus-estimates
Neurosense Therapeutics Stock Price History
August 13 at 10:47 PM  |  investing.comhttps://www.investing.com/equities/neurosense-therapeutics-historical-data
NeuroSense Issues CEO Letter to Shareholders
August 13 at 9:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-issues-ceo-letter-to-shareholders-302850917.html
Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) PT at $8.50
August 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30955803
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
August 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-completes-primec-pre-nds-process-and-advances-toward-december-2026-filing-with-health-canada-302845157.html
NeuroSense Therapeutics Calls August 26 Shareholder Vote on Wide-Range Reverse Share Split
July 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurosense-therapeutics-calls-august-26-shareholder-vote-on-wide-range-reverse-share-split?utm_source=marketbeat.com&utm_medium=referral
NeuroSense Updates Capital on Demand Program After New F-3 Becomes Effective
July 31, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurosense-updates-capital-on-demand-program-after-new-f-3-becomes-effective?utm_source=marketbeat.com&utm_medium=referral
Neurosense Therapeutics is a buy, this analyst says
July 28, 2026  |  cantechletter.comC
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
July 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-302832117.html
Neurosense Therapeutics Ltd. (NRSN) Gets a Buy from Noble Financial
July 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/NRSN/pressreleases/3116001/neurosense-therapeutics-ltd-nrsn-gets-a-buy-from-noble-financial/
NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)
July 8, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/nrsn/after-hours
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
July 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-to-participate-in-roth-hosted-kol-webinar-on-the-future-of-als-treatment-a-quest-to-outrun-als-302818300.html
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
June 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-achieves-primary-endpoint-in-phase-2b-als-study-with-statistically-significant-reduction-of-tdp-43-the-defining-pathological-hallmark-of-als-302813175.html
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
June 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-reports-positive-biomarker-findings-from-phase-2-road-proof-of-concept-study-of-primec-in-alzheimers-disease-302810686.html
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/everythingals-to-host-neurosense-in-a-community-event-named-primec---connecting-the-dots-302806305.html
NeuroSense Therapeutics (NASDAQ:NRSN) CEO Alon Ben-Noon Purchases 250,000 Shares
June 18, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-nrsn-insider-buying-and-selling-2026-06-18/
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
June 11, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-granted-south-korean-patent-covering-primec-composition-for-als-302797996.html
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neurosense-therapeutics-receives-japanese-patent-grant-for-primec-novel-composition-302795240.html
NRSN Share News Today
May 19, 2026  |  uk.investing.comhttps://uk.investing.com/equities/neurosense-therapeutics-news/1
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price
April 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neurosense-secures-insider-led-600000-pipe-at-premium-share-price?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bionomics stock logo

Bionomics NASDAQ:BNOX

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

KALA BIO stock logo

KALA BIO NASDAQ:KALA

$0.95 +0.03 (+2.81%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.90 -0.05 (-5.37%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Pasithea Therapeutics stock logo

Pasithea Therapeutics NASDAQ:KTTA

$0.48 +0.00 (+0.52%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.49 +0.01 (+2.81%)
As of 08/14/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

NeuroSense Therapeutics stock logo

NeuroSense Therapeutics NASDAQ:NRSN

$0.45 +0.01 (+2.26%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.46 +0.00 (+0.64%)
As of 08/14/2026 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas